发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
AIMS:Diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive lymphoid malignancies, which remains incurable, thus warranting the development of new therapies. Our previous study determined that rafoxanide is very effective in treating multiple myeloma (MM). In the present study, we tried to evaluate the effects of rafoxanide on DLBCL, as well as the potential underlying molecular mechanisms. MAIN METHODS:We used CCK-8 assay and flow cytometry to assess cell viability and apoptosis. The proteins and pathways associated with apoptosis and proliferation were evaluated through western blot, and xenograft mice were used as the experimental animal model. We also used the TUNEL assay and immunofluorescence for further analyses. KEY FINDINGS:Treatment with different doses of rafoxanide significantly inhibited cell viability and apoptosis. Additionally, the compound induced cell cycle arrest, reduced mitochondrial membrane potential (Δψm), and stimulated reactive oxygen species (ROS) generation without the influence of normal peripheral blood monocytes (PBMCs). As expected, rafoxanide played a role in regulating these proteins and the PTEN/PI3K/AKT and JNK/c-Jun pathways. Furthermore, immunofluorescence and western blot results showed that rafoxanide upregulated H2AX phosphorylation and then inhibited DNA repair in DLBCL. In the xenograft mouse model, tumor volumes were reduced after intraperitoneal injection with rafoxanide. We also observed that TUNEL positive cells were remarkably increased in rafoxanide-treated tumor tissues. SIGNIFICANCE:These results collectively provide a novel choice to regular treatment for DLBCL patients with poor prognosis.
展开更多
最新影响因子:6.78 | 期刊ISSN:0024-3205 | CiteScore:3.17 |
出版周期:Weekly | 是否OA:YES | 出版年份:1973 |
期刊官方网址:http://www.elsevier.com/wps/find/journaldescription.cws_home/525477/description
期刊投稿地址:http://ees.elsevier.com/lfs/
自引率:2.00% | 研究方向:医学-药学 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Life Sciences is an international weekly journal publishing reports on research in biomedical areas. Articles are encouraged that emphasize the molecular, cellular and functional aspects of Cardiovascular & Autonomic Mechanisms; Drug Metabolism; Endocrinology; Growth Factors and Neoplasia; Immunology; Neuroscience and Toxicology. The Journal publishes original research rapidly. Although full-length manuscripts are favored, shorter submissions are also considered. These shorter articles must be of the same high quality as full-length articles, and should contain information from topical and fast-moving fields in order to merit more rapid communication. Mini-reviews on topics of wide interest to investigators in the life sciences are also published. All articles are rigorously reviewed. The Journal favors publication of papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research.
《生命科学》是一份国际周刊,出版生物医学领域的研究报告。鼓励强调心血管和自主机制的分子、细胞和功能方面的文章;药物代谢;内分泌学;生长因子与肿瘤;免疫学;神经学和毒理学。该杂志迅速发表原创研究。虽然全篇幅的稿件更受欢迎,但也可以考虑提交较短的稿件。这些较短的文章必须与完整的文章具有相同的高质量,并且应该包含来自主题和快速移动领域的信息,以便进行更快速的交流。对生命科学研究人员广泛感兴趣的主题也发表了小型评论。所有文章都经过严格审查。该杂志倾向于发表现代科学技术用于解释分子、细胞和生理机制的论文。仅仅报告观察结果的文章很少被接受。必须遵守《赫尔辛基宣言》或国家卫生研究院关于护理和使用实验室动物的指导方针的建议。文章应该写在对文章主题本身不是专家,但对研究感兴趣的读者能够理解的水平上。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
MEDICINE, RESEARCH & EXPERIMENTAL (医学:研究与实验) 3区 PHARMACOLOGY & PHARMACY (药学) 3区 |
53/133 78/261 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
337 | 287 | 50 |
引文计数(2018)
文献(2015-2017)
4020次引用
1267篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Biochemistry, Genetics and Molecular Biology
小类(学科):General Biochemistry, Genetics and Molecular Biology
|
#41/187
点击查看排名表
|
|
2 |
大类(学科):Pharmacology, Toxicology and Pharmaceutics
小类(学科):General Pharmacology, Toxicology and Pharmaceutics
|
#4/68
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
研究方向:生命科学 生物物理、生物化学与分子生物学 生物化学
审稿时间: 1个月内
liting7111
研究方向:肝脏 缺血再灌注 氢气
审稿时间: 2个月内
liting7111
研究方向:生命科学 食品科学 食品科学基础
liting7111
liting7111
liting7111
liting7111
研究方向:炎症 内皮功能 血管
审稿时间: 3个月内 接受率: 中等(50%命中)
liting7111
审稿时间: 3个月内 接受率: 中等(50%命中)
liting7111
接受率: 中等(50%命中)
liting7111
研究方向:神经 衰老 阿尔兹海默症
审稿时间: 3个月内 接受率: 一般容易(75%命中)
liting7111
研究方向:生命科学 微生物学 微生物生理与生物化学
审稿时间: 4个月内
liting7111
liting7111
影响因子:6.497
ISSN:1172-7047
研究方向:医学-精神病学
影响因子:1.297
ISSN:0028-2804
研究方向:医学-精神病学
影响因子:4.604
ISSN:1092-8529
研究方向:医学-精神病学
影响因子:5.345
ISSN:1398-5647
研究方向:医学-精神病学
影响因子:3.492
ISSN:1540-2002
研究方向:CLINICAL NEUROLOGY-PSYCHIATRY
影响因子:4.562
ISSN:0269-8811
研究方向:医学-精神病学
影响因子:6.533
ISSN:0165-0327
研究方向:医学-精神病学
影响因子:5.415
ISSN:0924-977X
研究方向:医学-精神病学
影响因子:2.493
ISSN:0925-4927
研究方向:医学-精神病学
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
LIFE SCIENCES 投稿经验
(由下方点评分析获得,13人参与,92962人阅读)